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Abstract
Background: It has been suggested that dopamine dysfunction may play a role in bipolar disorder
(BD). An indirect approach to examine this issue was developed, focusing on associations between
dopamine proxy measures observed in BD (dopamine-related clinical traits using tardive
movement syndromes as dopamine proxy measure of reference).
Methods: 3459 eligible bipolar patients were enrolled in an observational study. Incidence rates
of tardive movement syndromes (tardive dyskinesia and tardive dystonia; TDD) were examined. A
priori hypothesized associations between incident TDD and other dopamine proxies (e.g.
prolactin-related adverse effects, bipolar symptoms) were tested over a 2 year follow-up period.
Results: The incidence rate of tardive syndromes was 4.1 %. Incident TDD was independently
associated not only with use of antipsychotics, but also with more severe bipolar symptoms, other
extrapyramidal symptoms and prolactin-related adverse effects of medication.
Conclusion: Apart from the well-known association with antipsychotics, development of TDD
was associated with various other dopamine proxy measures, indirectly supporting the notion of
generalised dopamine dysregulation in BD.
Background
Extrapyramidal symptoms (EPS) in general and tardive
dyskinesia (TD) in particular have been extensively stud-
ied in schizophrenia. Even though a number of studies
suggest that bipolar patients experience higher rates of
EPS (parkinsonism, dystonia, akathisia) and TD com-
pared to patients with a diagnosis of schizophrenia [1,2],
research within the bipolar disorder (BD) population has
been limited.
Berk and colleagues, reviewing converging data on the
role of dopamine (DA) in bipolar disorder, recently pos-
tulated the Dopamine Dysregulation Syndrome [3], based
on a consilience approach using research from a diversity
of domains, including preclinical, genetic, neuroimaging,
pharmacological and clinical research. The model pro-
poses a cyclical dysregulation in quantitative DA transmis-
sion in BD, the manic phase being associated with an
increase in DA transmission. Secondary down regulation
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of key elements and pre- as well as post-synaptic receptors
may subsequently decrease DA transmission, dampening
the cycle. A substantial reduction in DA transmission is
hypothesized to characterize the depressive phase, which
may be alleviated by secondary up-regulation of the same
key elements. Up and down regulation may be mediated
by endogenous homeostatic mechanisms; individual vul-
nerabilities exist to the hyper- and hypodopaminergic
state, explaining the large inter-individual variability in
illness course [3].
While of major interest, hypotheses about alterations in
DA function in severe mental illness are difficult to exam-
ine directly. It has been suggested, therefore, that altera-
tions in DA function in severe mental illness (i.e. illness
liabilities affecting various aspects of dopamine signaling,
separate from effects occasioned by antipsychotic medica-
tions) may be explored using clinical variables serving as
proximity measures (i.e. indirect measures) for DA neuro-
transmission in different DA tracts. These may include, for
example, presence of (i) prolactin-related adverse effects
as a proxy for alterations in the tuberoinfundibular tract
[4], ii) TD and EPS as proxies for alterations in the nigros-
triatal DA tract [5] whereas (iii) psychotic [5,6], manic [7]
and depressive [8] symptoms may reflect altered mesolim-
bic DA neurotransmission. Using these proxy measures in
a prospective study of schizophrenia patients, Tenback
and colleagues showed associations between incidence of
TD on the one hand and occurrence of EPS [9], prolactin-
related adverse effects [4] and worsening of psychotic
symptoms on the other [6], suggesting general DA dysreg-
ulation across the different DA tracts in schizophrenia.
The Dopamine Dysregulation Syndrome, as applied to BD
by Berk and colleagues [3], is currently limited to DA func-
tioning in the mesolimbic tract, focusing on mania and
depression. Similar to schizophrenia, associations
between the proxies representing alterations in the differ-
ent DA tracts may be hypothesized for bipolar disorder as
well. In order to test this hypothesis, DA dysfunction was
examined in a sample of patients with bipolar disorder,
using the proxy measures defined by Tenback et al [4,6].
In line with Tenback and colleagues [4,6], tardive move-
ment syndromes formed the reference outcome for the
analyses. Incidence rates of tardive extrapyramidal syn-
dromes were calculated, and associations between these
syndromes and proxy measures for alterations in other DA
tracts were examined.
Methods
Study design and population
EMBLEM (European Mania in Bipolar Evaluation of Med-
ication) was a 2-year prospective, observational study on
the outcome of pharmacological treatment of mania
across 14 European countries. A total of 3459 eligible in-
and outpatients were enrolled at the discretion of the
treating psychiatrist. Patients were eligible for participa-
tion if they were at least 18 years old and they initiated/
changed oral medication for treatment of acute mania in
bipolar disorder (antipsychotics, anticonvulsants and/or
lithium; not antidepressants or benzodiazepines) within
the standard course of care. During the acute treatment
phase, assessments took place at baseline and 1, 2, 3, 6
and 12 weeks after baseline. The maintenance phase con-
sisted of assessments at 6, 12, 18, and 24 months after
baseline. ERB approval and patient informed consent
were obtained according to local legal requirements. The
study design has been described in detail in previous
reports [10,11].
Extrapyramidal symptoms
Investigators were requested to assess presence and sever-
ity of parkinsonism, akathisia, dystonia and TD that they
judged to be associated with medications used to treat
bipolar disorder. This assessment was based on the inves-
tigator's clinical experience and judgment and rated as fol-
lows: 0 = not present; 1 = present, but does not
significantly interfere with patient's functioning; 2 =
present, and significantly interferes with patient's func-
tioning. Guided by previous analyses using these meas-
ures [4], movement disorder variables were analyzed as
dichotomous indicators (0 = not present versus 1 =
present; the latter combining scores of '1' and '2'). These
assessments were performed at baseline and all subse-
quent visits.
The scales used to measure extrapyramidal symptoms
were simple and did not include instructions on or spe-
cific anchors for differential diagnosis. Therefore, in order
to avoid diagnostic misclassification, only persistent dys-
tonia and TD were used in the current analyses. Using the
persistence measure ensured differentiation from the
acute syndromes, as, for example, acute dystonia would
be unlikely to persist over two subsequent visits whereas
tardive dystonia would. Persistence was defined as the
presence of the individual syndromes over at least 2 con-
secutive visits. Thus, the variable "persistent dystonia" was
rated as follows: 0 = no or acute/incidental dystonia; 1 =
persistent dystonia. Similarly, "persistent TD" was rated as
0 = no or incidental TD; 1 = persistent TD. Persistent TD
and persistent dystonia were analyzed together as a single
group (hereafter TDD: 0 = no persistent TD or persistent
dystonia present, 1 = persistent TD and/or persistent dys-
tonia present). The rational for combining TD and dysto-
nia comes from (i) their strong association [12,13], (ii)
shared risk factors and mechanisms [14,15] and (iii) the
fact that existing scales measuring tardive syndromes do
not differentiate between TD and tardive dystonia
[16,17]. Parkinsonism and akathisia were also compiled
into a single variable, hereafter named EPS (0 = neitherBMC Psychiatry 2009, 9:16 http://www.biomedcentral.com/1471-244X/9/16
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parkinsonism nor akathisia present, 1 = parkinsonism
and/or akathisia present).
Incidence of TDD
Incidence rates of TDD were determined by allocating
each patient person-time for the TDD outcome according
to the interval from baseline to the visit in which a patient
was diagnosed with TDD. If no such diagnosis was made,
the interval covered baseline to the final visit of each
patient. Nine time bands were constructed (baseline –
week 1; week 1 – week 2; week 2 – week 3; week 3 – 6
weeks; 6 weeks – 3 months; 3 months – 6 months; 6
months – 12 months; 12 months – 18 months; 18
months – 24 months). The incidence of TDD was calcu-
lated by dividing the total number of incident cases of
TDD by the total person-years. The same procedures were
followed for calculating separate incidence rates for tar-
dive dystonia and TD. All analyses were conducted in the
risk set of patients free of TDD at baseline.
Associations between clinical factors and incident TDD
Cox proportional hazard regression was used to assess
survival time without TDD associated with various time-
varying clinical variables. The following clinical measures
were used as proxies for DA dysregulation:
(i) Psychotic and manic symptoms may be associated
with high DA transmission in the mesolimbic pathway
[5,7]. Depression may be associated with lower DA trans-
mission in the same tract, even though different receptor
classes or sub-regions may be involved [5,8]. In the cur-
rent analyses, the CGI-BP severity of mania, CGI Halluci-
nations/delusions and CGI-BP depression were regarded
as proxy measures for altered DA transmission within the
mesolimbic DA tract. In addition, the CGI-BP overall ill-
ness was used as an overall measure of dysregulation in
this tract. All CGI scores were rated for severity on a seven-
point scale [18] and used at each visit including baseline.
(ii) Both amenorrhea and sexual dysfunction are associ-
ated with elevated prolactin levels induced by low DA
transmission [19,20] originating in the tuberoinfundibu-
lar DA tract. This link is likely stronger for amenorrhea, as
sexual disturbances in patients with schizophrenia are of
multifactorial origin, and are therefore only in part attrib-
utable to illness- or medication-related prolactin levels
[19,20]. Presence of amenorrhea and sexual dysfunction
were used as proxy measures for altered DA transmission
in the tuberoinfundibular tract (both defined as 0 = not
present; 1 = present; measured at each visit).
(iii) Extrapyramidal symptoms, including TD, have been
hypothesized to reflect low DA transmission in the nigros-
triatal DA tract in the brain [5]. Research indicates that
EPS (defined as parkinsonism, akathisia and acute dysto-
nia) represents a vulnerability to develop tardive move-
ment disorders, in particular tardive dyskinesia, in
patients with schizophrenia [9].
Therefore, presence of EPS as a proxy measure for dysfunc-
tional DA transmission in the nigrostriatal tract, was
tested for association with incident TDD.
(iv) Use of antipsychotics (APs) is known to affect
dopamine transmission [21] and in addition is strongly
associated with TD [5]. Use of AP was assessed at each
visit, and included in the analyses (0 = no AP use, 1 = first
generation antipsychotic (FGA), 2 = second generation
antipsychotic (SGA)).
The four clusters of proxy measures for DA dysfunction
(bipolar symptoms, prolactin-related adverse effects, EPS
and use of antipsychotics) were individually included as
independent variables in the Cox models in order to
determine associations with incident TDD. Finally, all var-
iables were entered simultaneously in the model in order
to determine which associations persisted independently
of other factors. Effect sizes were expressed as Hazard
Ratio's (HR) and 95% confidence intervals. The two-sided
significance level was 5%.
Adjustment by propensity score
Analyses were performed with and without confounders
(adjusted and unadjusted analyses, respectively). For each
analysis, all patients with non-missing values on the
dependent and independent variables were included, as
well as on all confounding variables in case of adjusted
analyses. Confounders were based on a review of the liter-
ature within patient populations diagnosed with bipolar
disorder, schizophrenia or psychotic disorders in general.
The following confounders were introduced in the Cox
regression models: social economic status (SES, expressed
as educational achievement; 1 = no education, 2 = pri-
mary school, 3 = secondary school lower, 4 = secondary
school upper, 5 = post-secondary vocational training, 6 =
university), country, compliance (0 = no medication pre-
scribed or always complies; 1 = never complies or 50% of
the time), age per decade [22,23], age of onset in years
[24], gender [23,25] and duration of illness in years [26].
As a decrease in TDD incidence over time was anticipated,
analyses were also adjusted for visit number.
It is common practice to increase the dosages of antipsy-
chotics or lithium in response to increased symptom
severity. It is widely accepted that antipsychotic use and
lithium in itself are associated with an increased risk for
developing movement disorders and other adverse effects
[5]. Thus, associations between higher symptom severity
or the presence of adverse effects with a higher incidence
of TDD may represent a confounding effect of AP or lith-BMC Psychiatry 2009, 9:16 http://www.biomedcentral.com/1471-244X/9/16
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ium use or dose burden. Therefore, except when testing
associations between TDD and the use of antipsychotics,
multiple treatment-related variables were included as con-
founders in order to eliminate spurious results for
dopamine abnormalities related to the (changes in) use of
antipsychotics and lithium. The following treatment-
related time-varying variables were included as confound-
ers: (i) use of APs (dichotomous variable: 0 = no use of AP,
1 = use of FGA and/or SGA); (ii) dichotomous variables
indicating use (0 = no use, 1 = use) of the following indi-
vidual treatments; amisulpride, clozapine, haloperidol,
olanzapine, quetiapine, risperidone, ziprazidone, other
AP or lithium (iii) dose of treatment used, expressed as
dose equivalents; (iv) change in dose of treatment with
respect to the previous visit, expressed as dose equivalents.
In addition, except when testing for an association
between the CGI-BP Overall illness and incident TDD,
change in CGI-BP Overall illness score relative to the pre-
vious visit was included as confounder.
As many confounding variables were included in the
models, traditional control for confounding by inclusion
of covariates in the model may not be sufficient, as the
degree of 'control' afforded by such models depends on
the overlap in characteristics between the two outcome
groups. The use of the propensity score has been suggested
as a means to obtain more complete control in these cir-
cumstances [27]. The propensity score for an individual,
defined as the conditional probability of (in this case)
developing TDD given the individual's covariates, can be
used to balance the covariates in observational studies,
and thus reduce bias [28]. In other words, by using pro-
pensity scores, a collection of covariates is replaced by a
single covariate, being a function of the original ones,
while minimizing the loss of degrees of freedom. As the
propensity score model could not create sufficient balance
between the groups due to the variable 'haloperidol',
haloperidol was not included in the propensity score
model and adjusted for separately in the model, together
with the dependent variable, the independent variable
under investigation and the propensity score representing
the other specified confounders.
Not all countries participated in the maintenance phase of
the study (12 weeks onwards), resulting in a decrease in
sample size after the 12 weeks (Switzerland, Denmark,
Germany and Spain only participated in the acute phase).
Apart from the decrease in overall sample size, the sam-
ples for the individual analyses varied somewhat on the
basis of the availability of complete data for variables
included in the separate models. All analyses were per-
formed using the computer package STATA, version 10.0
[29].
TDD validity: sensitivity analyses
Additionally, sensitivity analyses were conducted using a
stricter criterion for incidence in order to exclude any pos-
sibility of bias due to carry-over from influences occa-
sioned by factors acting during the period before baseline.
To this end, a stricter risk set was defined as the sample of
patients free from dystonia or TD at baseline as well as at
visit 2 (one week post-baseline). First occurrence of any
incident tardive syndrome could therefore occur at visit 3
(two weeks post-baseline), while for the purpose of the
current analyses incidence could first occur at visit 4, due
to the requirement of persistence of symptoms for at least
2 consecutive visits. Consequently, misclassification of
the acute form of dystonia, which usually has an onset
within 5 days of new antipsychotic treatment [30], could
be ruled out with even more confidence.
Results
A total of 3459 subjects participated in the EMBLEM study
and fulfilled the CGI-BP eligibility criteria (CGI-BP mania
≥ 3). 355 Patients were excluded from the analyses, either
due to missing baseline ratings of dystonia and/or TD, or
due to presence of dystonia and/or TD at baseline. Of the
remaining 3104 patients, 43.5% were male and the mean
age was 44.5 years (sd 13.4). The mean age of onset was
29.9 years (sd 11.1). Table 1 provides an overview of the
baseline clinical characteristics of the patient sample. As a
frame of reference, the medication used at enrollment, as
well as the medication prescribed at baseline are pre-
sented in Table 2. More than half of the patients did not
use any antipsychotic medication at enrollment, while
30% used antidepressants at that time. Second generation
APs were prescribed most frequently at the baseline visit,
followed by anticonvulsants.
Incidence rate
The TDD incidence was calculated by dividing the total
number of incident cases of TDD by the total person-
years. Over two years of treatment, the sample contributed
3163 patient years, while there were 129 new cases of
TDD, yielding an incidence rate of 4.1% (95% CI: 3.4,
4.8). The separate incidence rates for TD and Tardive Dys-
tonia were 1.0% (95% CI: 0.7, 1.4) and 3.3% (95% CI:
2.7, 4.0) respectively. Overall, incidence rates decreased
with time, as illustrated by Table 3, where incidence rates
are provided per time band.
Table 1: Baseline clinical characteristics of the total sample (n = 
3104).
Inpatient status (%) 40.0%
Rapid cycling (4 ≤ episodes per year; %) 17.2%
CGI-BP overall illness (mean, sd) 4.7 (1.0)
CGI-BP mania (mean, sd) 4.8 (1.0)
CGI Hallucinations/delusions (mean, sd) 2.9 (1.8)
CGI-BP depression (mean, sd) 1.8 (1.2)BMC Psychiatry 2009, 9:16 http://www.biomedcentral.com/1471-244X/9/16
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Associations between tardive dystonia and TD
In order to examine the validity of combining the tardive
dystonia and TD variables into a combined outcome,
associations between these tardive movement disorders
were calculated using Cox analyses. The probability of
incident tardive dystonia in the presence of TD was high
(HR = 9.56, 95% CI = 6.02, 15.18; P < .001), while the
probability of incident TD in the presence of tardive dys-
tonia was also high (HR = 22.25, 95% CI = 9.20, 53.85; P
< .001).
Associations between clinical factors and incident TDD
Table 4 provides associations between incident TDD and
hypothesized dichotomous variables; presence of sexual
dysfunction, amenorrhea and EPS were found to be asso-
ciated with incident TDD. Additionally, compared with
no AP use, both FGAs and SGAs showed a stronger associ-
ation with TDD. Associations between incident TDD and
hypothesized bipolar symptom severity are presented in
Table 5. Higher symptom severity was consistently found
to be associated with incident TDD.
Independence of associations with incident TDD
In order to test the degree of independence of the different
associations between TDD and the various DA-proxies, a
model with all predictors included together was exam-
ined. This revealed that the CGI-BP Hallucinations/delu-
sions (HR per CGI point = 1.13, 95% CI: 1.01, 1.28; P =
.041), sexual dysfunction (HR = 1.47, 95% CI: 1.12, 1.93;
P = .006) and presence of EPS (HR = 13.33, 95% CI: 5.01,
35.50; P < .001) were associated with incident TDD inde-
pendent of other factors.
Sensitivity analyses
The sample for the sensitivity analyses consisted of 2657
patients. The incidence rate for dystonia decreased to
2.2%, TD to 0.8% and TDD to 2.9%. All but one associa-
tion between DA-proxies and TDD remained significant
and effect sizes did not change substantially; only the
association between SGA use (versus no AP use) and TDD
was slightly reduced and no longer significant. Results are
included in Tables 4 &5.
Discussion
One in twenty-five participants experienced new onset tar-
dive dystonia and/or TD over a period of 2 years.
Although carry-over effects from previous medications
cannot be excluded because (i) the visits used to define
persistence were close to each other in time and (ii) there
was a linear decrease in incidence of TDD over the entire
Table 2: Medications at presentation and prescribed on baseline visit for the complete sample (n = 3104).
At presentation on baseline visit Prescribed at baseline visit†
No AP (%) 53.2% 11.1%
FGA (%) 25.4% 11.5%
SGA (%) 15.4% 65.3%
Combination of FGA and SGA (%) 6.0% 12.1%
Lithium (%) 18.8% 25.1%
Anticonvulsants (%) 29.9% 49.1%
Antidepressants (%) 30.0% 15.6%
Anticholinergics (%) * 8.8%
FGA = first generation antipsychotic; SGA = second generation antipsychotic; *not measured; †all patients were prescribed a new treatment at 
baseline; medication use is extensive in this population, therefore not all used medication is included in this table (e.g. benzodiazepines).
Table 3: Incidence of tardive dystonia, tardive dyskinesia and TDD for each time band (n = 3104).
Tardive dystonia TD TDD
N Person-years Incidence Rate N Person-years Incidence Rate Na Person-years Incidence Rate
Visit 3 (week 2) 37 114 32.6% 7 114 6.2% 41 114 36.1%
Visit 4 (week 3) 23 56 40,7% 4 57 7.0% 25 56 44.3%
Visit 5 (week 6) 15 141 10.6% 2 144 1.4% 17 141 12.0%
Visit 6 (month 3) 12 287 4.2% 4 293 1.4% 15 286 5.2%
Visit 7 (month 6) 5 440 1.1% 4 454 0.9% 8 439 1.8%
Visit 8 (month 12) 6 753 0.8% 5 776 0.6% 10 750 1.3%
Visit 9 (month 18) 2 721 0.3% 1 746 0.1% 3 716 0.4%
Visit 10 (month 24) 5 666 0.8% 6 688 0.9% 10 661 1.5%
The time band between visit 1 and 2 was not included, due to the definition of persistence (presence of symptoms for at least 2 consecutive visits). 
aAs some patients may present with both tardive dystonia and TD, N for TDD may be lower than the sum of N for tardive dystonia and TD.BMC Psychiatry 2009, 9:16 http://www.biomedcentral.com/1471-244X/9/16
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study period, the results from the sensitivity analyses sug-
gest that carry-over effects did not play an important role.
Indeed, even if carry-over effects existed, there is no reason
to assume that these should per se affect the reported asso-
ciations with third variables. Reported incidence rates of
tardive syndromes in bipolar populations vary widely in
the literature, probably due to variation in use of medica-
tion (type of antipsychotic, duration of exposure to lith-
ium, polypharmacy), tardive syndrome definitions,
characteristics of patient populations, study designs and
mood state dependent fluctuations [2]. Indeed, the sensi-
tivity analyses carried out for the purpose of the current
analyses clearly show that subtle changes in definition
affect incidence rates.
To our knowledge, rates of tardive dystonia have not been
reported in a similar population. One of the few reports
available on tardive dystonia originates from a sample of
chronic psychiatric patients from Curacao, mostly suffer-
ing from schizophrenia. The reported incidences for tar-
dive dystonia and TD were 0.7%, and 10.2%, respectively
[13], whereas in our sample tardive dystonia had a higher
incidence than TD. However, the Curacao study also
reported that the incidence of tardive dystonia diminished
over time, whereas the risk of TD followed an inverse pat-
tern [30]. This may explain the discrepancy with our cur-
rent findings, as the mean age in the current sample was
lower (mean age 44 years, sd 13) compared to the chron-
ically ill inpatient population from the Curacao study
(mean age 53 years, sd 17). Van Harten and colleagues
demonstrated that the rate of tardive dystonia was highest
in the age group of 44 years or younger, whereas the rate
of TD increased substantially after that age. Indeed, the
incidence rate for tardive dystonia in the current study
(3.3%; 2.3% when a stricter definition was applied),
approximates the 3% incidence rate reported for patients
on long-term antipsychotic treatment in a review by Van
Harten et al. [31]. More research is needed within the
bipolar spectrum to confirm the absolute risk of tardive
syndromes in this specific population.
Expanding the Dopamine Dysfunction Syndrome model?
A strong association was demonstrated between TDD inci-
dence and various clinical factors, beyond antipsychotic
medication, that were regarded as proxy measures for DA
dysfunction in different tracts: high symptom severity
scores, presence of sexual dysfunction, amenorrhea and
EPS. Thus, (proxy) dysfunction in the nigrostriatal tract
Table 4: Associations between incident TDD and various dichotomous clinical factors during a period of 2 years (n = 3104).
TDD rate exposed TDD rate non-exposed
Clinical factor N Person yearsa Rate (%) N Person years Rate (%) HR adjusted 
(95% CI)
HR unadjusted 
(95% CI)
Sensitivity analyses 
(HR adjusted) 95% 
CI)b
Sexual dysfunction 44 505 8.7 84 2637 3.2 2.68
(1.72, 4.16)*
2.72
(2.20, 3.37)*
2.61
(1.56, 4.39)*
Amenorrhea 11 126 8.7 107 2810 3.8 2.54
(2.10, 3.09)*
2.38
(1.74, 3.26)*
2.48
(1.83, 3.36)*
Extra-pyramidal 
symptoms
89 273 32.6 40 2875 1.4 13.94 (6.90, 
28.19)*
17.20
(9.11, 32.47)*
17.79
(6.70, 47.26)*
FGA use vs no AP 31 287 10.8 9 768 1.2 2.64 (1.94, 3.60)* 2.64
(1.97, 3.53)*
2.32
(1.66, 3.24)*
SGA use vs no AP 69 1902 3.6 9 768 1.2 2.18 (1.20, 3.97)† 2.16
(1.02, 4.54)†
1.50
(0.79, 2.85)
*P ≤ 0.001; †P ≤ 0.05 N = min. 1143 (as amenorrhea analysis was limited to women), max. 2025 for the adjusted analyses; n = min. 1606, max. 2953 
for the unadjusted analyses. aPerson years in follow-up. For instance, for sexual dysfunction, the patients included in the analyses contributed (505 + 
2637=) 3142 years of follow-up time. 44 patients that developed TDD presented with comorbid sexual dysfunction (rate of 8.7%). 84 patients that 
developed TDD did not present with comorbid sexual dysfunction (rate of 3.2%). bSensitivity analyses were conducted with a stricter criterion for 
incidence TDD; a stricter risk set was defined as the sample of patients free from dystonia or TD at baseline as well as at visit 2 (one week post-
baseline). Consequently, person-years included in this table do not hold for the sensitivity analyses.
Table 5: Associations between incident TDD and various continuous clinical factors over a 2-year period.
HR adjusted (95% CI interval) per 
CGI point
HR unadjusted (95% CI interval) 
per CGI point
Sensitivity analysis HR adjusted (95% 
CI interval) per CGI point
CGI-BP Overall illness 1.59 (1.32, 1.90)* 1.49 (1.24, 1.79)* 1.69 (1.44, 1.79)*
CGI-BP Hallucinations/delusions 1.53 (1.37, 1.70)* 1.49 (1.35, 1.64)* 1.60 (1.42, 1.80)*
CGI Mania 1.56 (1.36, 1.78)* 1.47 (1.24, 1.73)* 1.69 (1.53, 1.87)*
CGI-BP Depression 1.38 (1.12, 1.71)* 1.30 (1.14, 1.49)* 1.45 (1.18, 1.78)*
*P ≤ .002. N = min. 2013, max. 2016 for the adjusted analyses; n = min. 2948, max. 2952 for the unadjusted analyses.BMC Psychiatry 2009, 9:16 http://www.biomedcentral.com/1471-244X/9/16
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was found to be associated with (proxy) dysfunctions in
the mesolimbic and the tuberoinfundibular DA tracts,
indirectly suggesting generalised dopaminergic dysfunc-
tion.
The association between EPS and TDD was anticipated
based on similar findings in schizophrenia [9], and the
fact that extrapyramidal symptom clusters in general have
been linked to low DA transmission in the nigrostriatal
tract [5]. Associations between measures of sexual dys-
function and TDD are somewhat more complex as they
imply the involvement of different tracts; they are, how-
ever, both associated with relatively low DA transmission
[5,19,20].
Explaining the associations between more severe mania
and psychotic symptoms on the one hand, and incident
TDD on the other, is more complicated, as these symptom
clusters seemingly represent high rather than low states of
DA transmission, the latter being associated with TDD. To
the best of our knowledge, an association between psy-
chosis severity and TDD has not been reported before
within a bipolar population. One might argue that the
increase in psychotic symptoms and the emergence of
TDD may be occasioned simultaneously by withdrawal of
APs [32]. Alternatively, it may reflect increased dose of
antipsychotics prescribed in response to increases in psy-
chotic or manic symptoms, causing TDD. Although either
of these confounding mechanisms cannot be completely
excluded, it may be considered unlikely given that the cur-
rent analyses were adjusted for changes in AP use and
dose, as well as changes in CGI overall symptoms severity.
The association between more severe mania and TDD
incidence may be considered surprising, as the limited
reports available suggest a decrease of TD severity during
manic episodes [2]. It may be attractive to speculate, in
combination with the association found between TDD
and psychotic symptoms, that this finding can be
explained using the concept of 'supersensitivity psycho-
sis', which postulates that psychotic symptoms may be
produced by increased sensitivity of DA receptors in the
mesolimbic tract [33]. Manic symptoms, similar to psy-
chotic symptoms, have been linked to the mesolimbic DA
tract [5,7], suggesting that this theory may be extrapolated
to the mania symptom cluster as well. Although specula-
tive, the hypothesis that the concept of supersensitivity
may additionally extend to the nigrostriatal tract, could
explain the associations found in the current study.
This hypothesis could also explain the finding of decreas-
ing TDD incidence over time, as better BD symptom con-
trol might represent a dampening of supersensitivity,
which might be extended to multiple tracts. Another
explanation for this finding could be that patients who are
highly sensitive to TDD development would develop the
syndrome early in the study, whereas less sensitive
patients either develop the syndrome at a later stage or not
at all.
Even though the apparent contrast in the direction of
proxy DA transmission status in the mesolimbic (up regu-
lated) and nigrostriatal (down regulated) pathways that
were associated with TDD is difficult to explain, it is com-
patible with the notion of broad dysfunction in the DA
system. Alternatively, rather than an absolute interpreta-
tion of "high" or "low" states, DA instability or alterations
in regulatory influences among the different DA tracts
may instead represent the core characteristic driving the
observed associations. The limited conclusion that can be
drawn at this time is that more severe BD related symp-
toms are associated with an increased probability of tar-
dive syndromes, the reason for which remains speculative.
Limitations
The findings of the current study are subject to a number
of limitations. First, we depended on proxy measures of
DA transmission. The literature indicates that the investi-
gated symptoms and adverse effects are, to a certain
extent, related to DA dysfunction in certain areas. How-
ever, various external factors may influence these symp-
toms and effects without (necessarily) altering DA
transmission. For instance, use of concomitant medica-
tion or antagonism of other receptors by APs may affect
sexual dysfunction [19,20].
Second, if a pan-dopaminergic dysregulation exists within
BD, it remains unknown what may cause such a state. For
example, a reduction in sensitivity of postsynaptic DA
receptors, altered pre-synaptic activity, a reduction in
absolute or relative DA concentrations or another mecha-
nism yet to be revealed may be involved. Obviously, epi-
demiological research is not the appropriate methodology
to investigate these underlying mechanisms; more neu-
roimaging and pre-clinical data are needed to shed light
on the nature and extent of DA dysfunction within the
framework of the hypothesized dopamine dysregulation
syndrome proposed by Berk and colleagues [3] as well as
the extensions proposed in the current report.
Third, as cogently discussed by Berk and colleagues, DA
transmission is certainly not the sole underlying factor for
neural dysfunction in BD; other neurotransmitters are
likely to play a role. Even though the current model is far
from able to explain all pathology associated with BD, the
current literature is not incompatible with a major role of
DA. Therefore, the model used may be regarded as an
interesting scientific starting point for epidemiological
research on the extent and nature of any involvement of
DA in the bipolar spectrum.BMC Psychiatry 2009, 9:16 http://www.biomedcentral.com/1471-244X/9/16
Page 8 of 9
(page number not for citation purposes)
Fourth and final, the direct effects of lithium or antipsy-
chotics dose adjustments on tardive movement disorders
are complicated. Tardive dyskinesia has been reported to
abate after dose increases [34], usually to reappear after
some time, whereas acute dystonia often emerges follow-
ing dose increases [5]. In order to avoid confounding,
analyses were controlled for various relevant treatment-
related variables, including changes in treatment doses.
Even with this adjustment, one could question the extent
to which dose adjustments may have influenced our
results.
Conclusion
Apart from the well-known association with antipsychot-
ics, development of TDD was associated with various
other dopamine proxy measures, indirectly supporting
the notion of generalized dopamine dysregulation in BD.
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